Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Brain nitric oxide synthase (NOS), which utilizes NADPH and calcium/calmodulin as cofactors for metabolizing L-arginine to nitric oxide (NO) and
L-citrulline
, contains recognition sites for the flavins FAD and FMN. Using a spin-trapping technique combined with electron spin resonance spectroscopy, we report that brain NOS generates superoxide O2-. in a calcium/calmodulin-dependent manner. The "specific inhibitors" of NOS, NG-monomethyl L-arginine (L-NMMA), and NG-nitro-L-arginine methyl ester (L-
NAME
), have different effects on O2-. generation. For L-NMMA, O2-. production is unaffected, while for L-
NAME
, inhibition of this free radical is concentration-dependent.
...
PMID:Generation of superoxide by purified brain nitric oxide synthase. 128 Feb 57
1. The effects of L-NG-nitro-arginine (L-NOARG) and some other arginine analogues on non-adrenergic, non-cholinergic (NANC) relaxations of the rat anococcygeus muscle were investigated. 2. L-NOARG (5-200 microM) produced concentration-related inhibition of the NANC response; 100 microM L-NOARG produced 90% inhibition. 3. L-Arginine (5-200 microM) produced a concentration-related reversal of the inhibitory effect of 20 microM L-NOARG; a five fold excess of L-arginine (100 microM) was required to obtain the maximum reversal of 90%. D-Arginine (100 microM) produced no such reversal, but significant reversal was produced by
L-citrulline
, L-arginine-L-aspartate, L-homoarginine and L-arginine-methyl-ester (all at 100 microM). 4. L-NG-nitro-arginine-methyl-ester (L-
NAME
; 5-200 microM) also reduced NANC relaxations, with a potency similar to that of L-NOARG; both L-NOARG and L-
NAME
were some ten times more potent than L-NG-monomethyl-arginine (L-NMMA). Like L-NOARG, the effects of L-
NAME
(20 microM) were reversed by 100 microM L- but not D-arginine. 5. Neither L-NOARG nor L-
NAME
(both 20 microM) affected submaximal relaxations induced by 10 microM sodium nitroprusside or 20 microM hydroxylamine. 6. D-NOARG, L-NG-tosyl-arginine and L-N alpha-(t-butyl-oxycarbonyl)-NG-nitro-arginine (all at 100 microM) had no effect on NANC relaxations. 7. Thus, in the rat anococcygeus, L-NOARG and L-
NAME
are more potent than L-NMMA as prejunctional inhibitors of NANC transmission. The reversibility of the effect of L-NOARG by arginine analogues suggests that the NANC system of the anococcygeus shows similarities to the endogenous nitrate system recently described in the brain.
...
PMID:L-NG-nitro-arginine and its methyl ester are potent inhibitors of non-adrenergic, non-cholinergic transmission in the rat anococcygeus. 216 39
Endotoxin (Escherichia coli lipopolysaccharide 0111:B4, 3 mg/kg i.v.) induced the expression of a calcium-independent nitric oxide (NO) synthase, determined after 5 h in cardiac, hepatic, pulmonary and renal tissues, as assessed by the conversion of radiolabelled L-arginine to
L-citrulline
. This widespread induction of NO synthase in these conscious rats was associated with microvascular injury, as assessed by the vascular leakage of radiolabelled human serum albumin. Concurrent administration of the NO synthase inhibitor. NG-nitro-L-arginine methyl ester (L-
NAME
, 1-5 mg/kg s.c.) with endotoxin, provoked acute vascular leakage within 2 h in the various organs. By contrast, the delayed injection of L-
NAME
(1-5 mg/kg s.c.) or NG-monomethyl-L-arginine (12.5-50 mg/kg s.c.) until 3 h after endotoxin challenge inhibited the subsequent microvascular leakage in these organs. These effects of NO synthase inhibitors were reversed by L-arginine (300 mg/kg s.c.) pretreatment. These results support a protective role of constitutive NO synthase in the early phase of endotoxin shock. Such actions contrast with the aggressive actions of the products of inducible NO synthase in the development of widespread microvascular injury in endotoxemic states.
...
PMID:Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs. 749 20
Amino acid transport systems mediating uptake of nitric oxide (NO) synthase inhibitors were characterized in the murine macrophage cell line J774. Treatment of J774 cells with bacterial endotoxin (LPS, 1 microgram ml-1, 24 h) selectively increased the transport capacity for NG-monomethyl-L-[14C]arginine (L-NMMA), whereas transport of NG-nitro-L-[3H]arginine (L-NNA) was unaffected. Inhibition studies established that the cationic transport system y+ mediates uptake of L-arginine, L-NMMA and NG-iminoethyl-L-ornithine (L-NIO). A neutral transporter, with low substrate specificity and insensitive to LPS, mediates uptake of
L-citrulline
, L-NNA and its methyl ester L-
NAME
. We conclude that enhanced expression of the y+ transporter in LPS-stimulated macrophages may facilitate the targeting of selective inhibitors of inducible NO synthase to activated cells generating NO in endotoxin shock.
...
PMID:Selective targeting of nitric oxide synthase inhibitors to system y+ in activated macrophages. 751 94
We studied the dose-response characteristics and the temporal profile of inhibition of brain nitric oxide (NO) synthase (NOS) elicited by i.v. administration of the NOS inhibitor nitro-L-arginine methyl ester (L-
NAME
). L-
NAME
was administered i.v. in awake rats equipped with a venous cannula. L-
NAME
was injected in cumulative doses of 5, 10, 20 and 40 mg/kg and rats were sacrificed 30 min after the last dose. NOS catalytic activity was assayed in forebrain cytosol as the conversion of [3H]L-arginine into [3H]
L-citrulline
. L-
NAME
attenuated brain NOS activity in a dose-dependent manner but enzyme activity could not be inhibited by more than approximately 50%. After a single 20 mg/kg injection of L-
NAME
the inhibition of brain NOS activity was time dependent and reached a stable level at 2 hrs (52% of vehicle). Inhibition after a single injection was still present at 96 hrs, albeit to a lower magnitude. We conclude that intravenous administration of L-
NAME
in rats at concentrations commonly used in physiological experiments leads to a dose and time-dependent but partial inhibition of brain NOS catalytic activity. The finding that the inhibition persists for several days after a single administration is consistent with the hypothesis that nitro-L-arginine, the active principle of L-
NAME
, binds to NOS irreversibly.
...
PMID:Prolonged inhibition of brain nitric oxide synthase by short-term systemic administration of nitro-L-arginine methyl ester. 752 May 40
Although high-density lipoprotein (HDL) has been found to decrease platelet function per se, little is known regarding the mechanism of its platelet inhibitory effect. In this study, we confirmed the inhibitory effect of HDL on platelet aggregation and 14C-serotonin release in thrombin-activated washed human platelets. The inhibition of platelet function was associated with an increase in nitric oxide synthase activity, measured as the conversion of 3H-L-arginine to 3H-
L-citrulline
as well as nitrite release in the platelet supernates. The inhibition of platelet function by HDL was reversed by preincubation of washed platelets with an inhibitor of nitric oxide synthase, NG-nitro-L-arginine methyl ester (L-
NAME
), and potentiated by co-incubation with the precursor of nitric oxide, L-arginine. These observations suggest that HDL decreases platelet function by increasing nitric oxide synthase activity in human platelets.
...
PMID:Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. 752 5
In the present study, we have characterized the renal response to inhibition of endogenous nitric oxide (NO) synthesis [intravenous NG-nitro-L-arginine methyl ester (L-
NAME
) for 3 h] in anesthetized cirrhotic rats, with (ASC) and without (
CIR
) ascites, at doses that do not change blood pressure (BP). Administration of L-
NAME
induced opposite effects on water (UV) and sodium (UNaV) excretion in cirrhotic and control animals. Infusion of 1 microgram.kg-1.min-1 of L-
NAME
in
CIR
(n = 5) decreased renal plasma flow (RPF) at the end of the 3-h period, whereas UV, UNaV, and glomerular filtration rate (GFR) were unaltered. In contrast, infusion of L-
NAME
at 10 micrograms.kg-1.min-1 in six more
CIR
increased UV and UNaV significantly by the 1st h, without changes in BP or GFR, and these parameters remained elevated throughout the experiment. Infusion of 1 microgram.kg-1.min-1 in ASC (n = 6) did not change BP or GFR but significantly enhanced UV and UNaV after the 1st h. These effects were prevented by pretreatment with L-arginine (0.1 mg.kg-1.min-1) in another group of ASC infused with 1 microgram.kg-1.min-1 of L-
NAME
. These results indicate that, in ASC and
CIR
cirrhotic rats, inhibition of NO synthesis at nonpressor does improves renal excretion of sodium and water via a decrease in tubular reabsorption. NO is an important mediator of the renal excretory and hemodynamic alterations of experimental liver cirrhosis.
...
PMID:Renal effects of nitric oxide synthesis inhibition in cirrhotic rats. 752 2
1. The effects of three analogues of NG-nitro-L-arginine (L-NOARG) and NG-monomethyl-L-arginine (L-NMMA), inhibitors of nitric oxide (NO) synthase, on hydrogen peroxide (H2O2)-induced endothelial cell injury were studied. 2. Endothelial cell injury was assessed by measuring the release of intracellular lactate dehydrogenase (LDH) and 51Cr. 3. Addition of H2O2 (250-1,000 microM) to endothelial cells induced the release of LDH dose-dependently. The release of LDH was reduced by pretreatment with NG-nitro-L-arginine methyl ester (L-
NAME
, 10(-4)-4 x 10(-3) M), L-NOARG (10(-4)-4 x 10(-3) M) and NG-nitro-L-arginine benzyl ester (L-NABE, 10(-4)-4 x 10(-3) M), inhibitors of NO synthase. 4. L-NOARG analogues also reduced H2O2-induced 51Cr release from endothelial cells, while L-NMMA had no effect. 5. The protective effect of L-
NAME
was not reversed by addition of L-arginine (L-Arg, 1-10 mM). 6. Both L-
NAME
and L-NMMA completely inhibited L-Arg metabolism to
L-citrulline
coupled with NO synthesis. 7. These findings suggest that L-NOARG analogues but not L-NMMA reduced H2O2-induced endothelial cell injury, and that these effects may not be related to inhibition of NO production.
...
PMID:Reduction by NG-nitro-L-arginine of H2O2-induced endothelial cell injury. 753 May 74
Stimulation of N-methyl-D-aspartate (NMDA) receptors in brain increases nitric oxide production in vitro. We tested the hypothesis that nitric oxide participates in the increase in local cerebral blood flow (CBF) caused by infusion of NMDA in anesthetized newborn sheep. We used the combined hydrogen clearance and microdialysis technique for simultaneous measurement of local CBF, infusion of drugs, and measurement of interstitial levels of L-[14C]citrulline in the parietal cortex. Release of L-[14C]citrulline into the dialysate during continuous infusion of L-[14C]arginine was used as a marker of nitric oxide production in vivo.
Citrulline
recovery and CBF were measured hourly during a 4-h infusion of cerebrospinal fluid containing either 1) no additional drugs, 2) 1 mM NMDA, 3) 1 mM NG-nitro-L-arginine methyl ester (L-
NAME
, a nitric oxide synthase inhibitor), 4) 1 mM NMDA + 1 mM L-
NAME
, 5) 0.1 mM 2-chloroadenosine (adenosine receptor agonist), or 6) 0.1 mM 2-chloroadenosine + 1 mM L-
NAME
. At 240 min of perfusion, CBF (ml.min-1.100 g-1; means +/- SE) was as follows: control 52 +/- 3, NMDA 116 +/- 11, L-
NAME
32 +/- 5, NMDA+L-
NAME
40 +/- 4,2-chloroadenosine 201 +/- 63, and 2-chloroadenosine+L-
NAME
129 +/- 18.
Citrulline
recovery (fmol/min) at 240 min of perfusion was as follows: control 38 +/- 12, NMDA 149 +/- 21, L-
NAME
9 +/- 1, NMDA+L-
NAME
39 +/- 5, 2-chloroadenosine 13 +/- 5, and 2-chloroadenosine+L-
NAME
17 +/- 1.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:In vivo production of nitric oxide correlates with NMDA-induced cerebral hyperemia in newborn sheep. 763 51
Endothelial cell nitric oxide synthase (ECNOS) is a membrane-associated enzyme that generates endothelium-derived relaxing factor/nitric oxide (EDRF/NO) from L-arginine. We have suggested, from the cloning of the bovine ECNOS cDNA, that the presence of an N-myristoylation consensus sequence may impart its membrane localization since cytosolic forms of NOS do not contain such domains. To test the hypothesis that N-myristoylation is necessary for particulate ECNOS, we performed site-directed mutagenesis of the myristic acid acceptor site, Gly-2, and changed the glycine codon to alanine by a single nucleotide substitution. Expression of wild-type ECNOS in COS cells resulted in greater than 95% of the enzymatic activity in crude membrane fractions (as measured by the conversion of [3H]L-arginine to [3H]
L-citrulline
). In contrast, expression of the Gly-2 to Ala-2 mutant (G2A) demonstrated 8% ECNOS activity in membranes and 92% in the cytosol. The back mutation (from Ala-2 to Gly-2, A2G) restored ECNOS activity to the particulate fraction as seen with the wild type. Both wild-type membrane ECNOS and cytosolic G2A ECNOS activities were dependent on NADPH and calcium and were inhibited to the same extent by NG-monomethyl L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-
NAME
). Moreover, kinetic analysis of these enzymes revealed similar Kms for L-arginine (2-4 microM, n = 3), demonstrating that the mutation did not affect ECNOS function. Thus, N-myristoylation is necessary for the membrane localization of ECNOS and may be of special significance for the basal or flow-induced production of NO by the endothelium.
...
PMID:Mutation of N-myristoylation site converts endothelial cell nitric oxide synthase from a membrane to a cytosolic protein. 768 Feb 89
1
2
3
4
5
6
7
Next >>